- Natera Inc. (NTRA, Financial) will present data from eight studies at the 2025 AACR Annual Meeting.
- Studies cover genomic profiling in colorectal, breast, and gynecological cancers.
- Presentations highlight the use of Signatera™ in improving immunotherapy response predictions.
Natera Inc. (NTRA), a global leader in cell-free DNA and genetic testing, announced its participation in the 2025 American Association of Cancer Research (AACR) Annual Meeting scheduled for April 25 – 30, in Chicago, IL. The company will present comprehensive data from eight studies, showcasing advancements in genomic profiling and immunotherapy response prediction.
The event will feature an oral presentation on "Large-scale Genomic Profiling of Colorectal Cancer," utilizing data from over 73,000 patients who underwent commercial Signatera™ testing. This research explores the mutational landscape of colorectal cancer (CRC) and patterns within clinical and molecular subgroups.
Additionally, poster presentations will delve into the genomic landscape of over 30,000 breast cancer patients and more than 8,000 gynecologic cancer patients. These studies reveal distinct genomic patterns and underscore the value of Natera's real-world database (RWD) in oncological research.
Natera's integrated clinical and genomic data are also pivotal in enhancing immunotherapy response prediction through improved neoantigen identification. Further datasets in esophageal cancer, sarcoma, and CRC add to the validation of Signatera's clinical utility.
"We are pleased to share such a broad set of data showcasing our breadth of capabilities in oncology," stated Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer for Natera.
Signatera™ is a personalized, tumor-informed molecular residual disease test designed to detect and quantify cancer presence and optimize treatment decisions. It is clinically validated across various cancer types, supported by more than 100 peer-reviewed publications, and covered by Medicare for a wide range of indications.
